Glecaprevir & Pibrentasvir
- TRADE NAME: Mavyret (AbbVie)
- INDICATIONS: Chronic HCV genotype 1–6 infection
- CLASS: Direct-acting antiviral, Hepatitis C virus NS3/4A protease inhibitor (glecaprevir), Hepatitis C virus NS5A inhibitor (pibrentasvir)
- HALF-LIFE: 6 hours (glecaprevir); 13 hours (pibrentasvir)
FDA APPROVAL DATE: 08/03/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Atazanavir, Atorvastatin, Carbamazepine, Cyclosporine, Darunavir, Efavirenz, Lopinavir, Lovastatin, Oral Contraceptives, Rifampin, Ritonavir, Simvastatin, St John's Wort
PREGNANCY CATEGORY: N/A
Insufficient evidence to inform drug-associated risk
Contra-indicated in patients with severe hepatic impairment (Child-Pugh C).
RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric